Georgia lawmakers are hoping to pass a bill before the legislative session ends Friday that would allow pharmacists to distribute HIV prevention medicines without a prescription, a policy change that ...
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Zacks Investment Research on MSN2d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...
On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the ...
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback